Abstract
Esophageal adenocarcinoma is one of the fastest rising cancers in Western society. Incidence has increased by 600% within the last 30 years. Rates of diagnosis and death run parallel due to the poor prognosis and a lack of effective treatments. Potentially curative treatments are followed by high rates of disease recurrence. For the majority of patients, who present with advanced disease, we have no effective treatment. We discuss the key areas of progress in this demanding field and offer our views on the direction of future research and treatment.
Keywords:
Barrett’s esophagus; esophageal adenocarcinoma; esophageal cancer; esophageal cancer diagnosis; esophageal cancer prevention; esophageal cancer treatment; gastro esophageal reflux disease.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adenocarcinoma / diagnosis
-
Adenocarcinoma / etiology
-
Adenocarcinoma / mortality
-
Adenocarcinoma / prevention & control
-
Adenocarcinoma / therapy*
-
Antineoplastic Agents / therapeutic use
-
Aspirin / therapeutic use
-
Barrett Esophagus / diagnosis
-
Barrett Esophagus / therapy
-
Combined Modality Therapy
-
Cytodiagnosis / instrumentation
-
Cytodiagnosis / methods
-
Early Detection of Cancer
-
Esophageal Neoplasms / diagnosis
-
Esophageal Neoplasms / etiology
-
Esophageal Neoplasms / mortality
-
Esophageal Neoplasms / prevention & control
-
Esophageal Neoplasms / therapy*
-
Esophagectomy
-
Esophagoscopy
-
Forecasting
-
Fundoplication
-
Gastroesophageal Reflux / complications
-
Gastroesophageal Reflux / drug therapy
-
Gastroesophageal Reflux / surgery
-
Health Promotion
-
Humans
-
Male
-
Middle Aged
-
Neoadjuvant Therapy
-
Precancerous Conditions / diagnosis
-
Precancerous Conditions / therapy
-
Proton Pump Inhibitors / therapeutic use
-
Treatment Outcome
-
Tumor Microenvironment
Substances
-
Antineoplastic Agents
-
Proton Pump Inhibitors
-
Aspirin